NCT04456959 - InO - A Retrospective Study of UK Patients With Leukaemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

January 27, 2021

Study Completion Date

January 27, 2021

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

DRUG

Inotuzumab Ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of a recombinant humanised IgG4 kappa CD22-directed monoclonal antibody (produced in Chinese hamster ovary cells by recombinant DNA technology) that is covalently linked to N-acetyl-gamma-calicheamicin dimethylhydrazide.

Trial Locations (4)

BS1 3NU

University Hospitals Bristol NHS Foundation Trust, Bristol

NW1 2PG

University College London Hospital NHS Foundation Trust, London

SW3 6JJ

The Royal Marsden NHS Foundation Trust of Fulham Road, London

TA1 5DA

Taunton and Somerset NHS Foundation Trust of Musgrove Park Hospital, Taunton